Menu Back toA Collaborative Cross-Company Pediatric Platform Trial in Pediatric Crohn’s Disease Using an Innovative Bayesian Analysis

DIA 2021 Global Annual Meeting


A Collaborative Cross-Company Pediatric Platform Trial in Pediatric Crohn’s Disease Using an Innovative Bayesian Analysis

Session Chair(s)

Robert  Nelson, MD, PhD

Robert Nelson, MD, PhD

  • Senior Director, Pediatric Drug Development (CHILD)
  • Johnson & Johnson, United States
Innovative approaches to pediatric drug development are needed to reduce the delay between adult and pediatric marketing approval. This session presents a cross-company pediatric platform trial in Crohn's disease using a Bayesian analysis.
Learning Objective : Identify some of the recruitment challenges in pediatric drug development; Identify the role of platform trials in addressing these challenges; Discuss the clinical, scientific, regulatory, and operational challenges in designing and implementing a cross-company pediatric platform trial.

Speaker(s)

Laurie  Conklin, DrMed, MD

Industry Update

Laurie Conklin, DrMed, MD

  • Director, Pediatric Immunology
  • Janssen, United States
Wendy  Komocsar

Industry Update

Wendy Komocsar

  • Research Advisor, Immunology
  • Eli Lilly and Company , United States
Forrest  Williamson, PhD

Industry Update

Forrest Williamson, PhD

  • Senior Research Scientist, Statistics Data and Analytics
  • Eli Lilly and Company, United States